The Oncosearch | Oncotarget

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Kwang Woon Kim, Julia Y. Kim, Jingbo Qiao, Rachael A. Clark, Camille M. Powers, Hernan Correa, Dai H. Chung

Published Sep 5, 2019

Keywords: chemotherapy, radiotherapy, resistance, AKT2, MAPK

Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma Research Paper

Kimberly J. Riehle, Heidi L. Kenerson, Kevin M. Riggle, Rigney Turnham, Kevin Sullivan, Renay Bauer, John D. Scott, Raymond S. Yeung

Published Aug 20, 2019 · Vol. 10, No. 49 · pp. 5092-5102

Keywords: liver cancer, protein kinase A, fibrolamellar, neurotensin, epidermal growth factor

Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma Research Paper

Osamu Ichiyanagi, Hiromi Ito, Sei Naito, Takanobu Kabasawa, Hidenori Kanno, Takafumi Narisawa, Masaki Ushijima, Yuta Kurota, Michinobu Ozawa, Toshihiko Sakurai, Hayato Nishida, Tomoyuki Kato, Mitsunori Yamakawa, Norihiko Tsuchiya

Published Jun 18, 2019 · Vol. 10, No. 40 · pp. 4053-4068

Keywords: renal cell carcinoma, phospho-eIF4E (p-eIF4E), MNK (MAPK-interacting kinase), recurrence-free, epithelial−mesenchymal transition

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Peter Y.M. Woo, Tai-Chung Lam, Jenny K.S. Pu, Lai-Fung Li, Roland C.Y. Leung, Jason M.K. Ho, James T.F. Zhung, Belinda Wong, Timonthy S.K. Chan, Herbert H.F. Loong, Ho-Keung Ng

Published Jun 4, 2019 · Vol. 10, No. 38 · pp. 3818-3826

Keywords: glioblastoma, BRAF^V600E mutation, targeted therapies, BRAF-MEK inhibitors

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt Research Paper

Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá

Published Apr 2, 2019 · Vol. 10, No. 26 · pp. 2486-2507

Keywords: hydroxytriolein, membrane lipid therapy, lipid composition and cancer treatment, autophagy, triple negative breast cancer

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Ruth Halaban, Antonella Bacchiocchi, Robert Straub, Jian Cao, Mario Sznol, Deepak Narayan, Ahmed Allam, Michael Krauthammer, Tarek S. Mansour

Published Mar 19, 2019 · Vol. 10, No. 23 · pp. 2237-2251

Keywords: melanoma, SRC-family kinase inhibitors, MAPK, MITF

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma Research Paper

Carla M.L. van Herpen, Sanjiv S. Agarwala, Axel Hauschild, Carola Berking, J. Thaddeus Beck, Dirk Schadendorf, Rob Jansen, Paola Queirolo, Paolo A. Ascierto, Christian U. Blank, Michael C. Heinrich, Rupam R. Pal, Adnan Derti, Victor Antona, Heidi Nauwelaerts, Angela Zubel, Reinhard Dummer

Published Mar 5, 2019 · Vol. 10, No. 19 · pp. 1850-1859

CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition Research Paper

Jasmin B. Post, Nizar Hami, Alexander E.E. Mertens, Suraya Elfrink, Johannes L. Bos, Hugo J.G. Snippert

Published Feb 15, 2019 · Vol. 10, No. 14 · pp. 1440-1457

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

Stephanie A. Toll, Hung N. Tran, Jennifer Cotter, Alexander R. Judkins, Benita Tamrazi, Jaclyn A Biegel, Girish Dhall, Nathan J. Robison, Kaaren Waters, Palak Patel, Robert Cooper, Ashley S. Margol

Published Jan 11, 2019 · Vol. 10, No. 4 · pp. 551-557

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer News

Carmelo Nucera

Published Jan 10, 2019 · Vol. 10, No. 7 · pp. 686-687

MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule Research Paper

Felix Grabenbauer, Astrid Katzer, Dmitri Sisario, Simon Memmel, Michael Flentje, Vladimir L. Sukhoruko, Cholpon S. Djuzenova

Published Dec 21, 2018 · Vol. 9, No. 100 · pp. 37379-37392

Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas Research Paper

James L. Figarola, Jyotsana Singhal, Sharad Singhal, Jyotirmoy Kusari, Arthur Riggs

Published Dec 11, 2018 · Vol. 9, No. 97 · pp. 36945-36965

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth Correction

Kimberley Hanson, Stephen D. Robinson, Karamallah Al-Yousuf, Adam E. Hendry, Darren W. Sexton, Victoria Sherwood, Grant N. Wheeler

Published Nov 27, 2018 · Vol. 9, No. 93 · pp. 36645-36645

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

Xuguang Zhu, Erik Holmsen, Sunmi Park, Mark C. Willingham, Jun Qi, Sheue-yann Cheng

Published Oct 23, 2018 · Vol. 9, No. 83 · pp. 35408-35421

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas Research Paper

Christian Posch, Martina Sanlorenzo, Jeffrey Ma, Sarasa T. Kim, Mitchell Zekhtser, Susana Ortiz-Urda

Published Oct 9, 2018 · Vol. 9, No. 79 · pp. 34990-34995

Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma Research Paper

Xuran Yang, Wei Xia, Lin Chen, Chuan Xing Wu, Cathy C. Zhang, Peter Olson, Xiao Qi Wang

Published Oct 9, 2018 · Vol. 9, No. 79 · pp. 34996-35007

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study Research Paper

Julia K. Tietze, Andrea Forschner, Carmen Loquai, Heidrun Mitzel-Rink, Lisa Zimmer, Frank Meiss, David Rafei-Shamsabadi, Jochen Utikal, Maike Bergmann, Friedegund Meier, Nicole Kreuzberg, Max Schlaak, Carsten Weishaupt, Claudia PfÃ¶hler, Mirjana Ziemer, Michael Fluck, Jessica Rainer, Markus V. Heppt, Carola Berking

Published Sep 28, 2018 · Vol. 9, No. 76 · pp. 34336-34346

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

Katelyn N. Nelson, April N. Meyer, Clark G. Wang, Daniel J. Donoghue

Published Sep 28, 2018 · Vol. 9, No. 76 · pp. 34306-34319

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer Priority Research Paper

Eric Haines, Ting Chen, Naveen Kommajosyula, Zhao Chen, Grit S. Herter-Sprie, Liam Cornell, Kwok-Kin Wong, Geoffrey I. Shapiro

Published Aug 3, 2018 · Vol. 9, No. 60 · pp. 31572-31589

The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation Research Paper

Taiane Schneider, Arturo Martinez-Martinez, Monica Cubillos-Rojas, Ramon Bartrons, Francesc Ventura, Jose Luis Rosa

Published Jul 31, 2018 · Vol. 9, No. 59 · pp. 31531-31548

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma Research Paper

Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt Research Paper

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma Research Paper

CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition Research Paper

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer News

MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule Research Paper

Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas Research Paper

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth Correction

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas Research Paper

Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma Research Paper

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study Research Paper

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer Priority Research Paper

The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma Research Paper

Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma Research Paper

Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt Research Paper

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma Research Paper

CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition Research Paper

Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer News

MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule Research Paper

Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas Research Paper

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth Correction

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas Research Paper

Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma Research Paper

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study Research Paper

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer Priority Research Paper

The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report